Eric Weinstein, MD
Critical Care Medicine · Cincinnati, OHNPI 1962534693
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 235 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 32 manufacturers reported payments, led by GSK at 24.6% of the total. Reporting peaked in 2023 at $1,172 and has fallen 57.8% since, to $494 in 2025.
Across 235 payments — averaging $17.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AstraZeneca$506
- Sanofi$432
- Boehringer Ingelheim$299
- Pulmonx Corporation$227
- Grifols USA, LLC$185
- plus $1K from 26 others
What the payments were for
- Food & beverage$4,055100%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 84 | $1,003 |
| AstraZeneca | 21 | $506 |
| Sanofi | 25 | $432 |
| Boehringer Ingelheim | 16 | $299 |
| Pulmonx Corporation | 6 | $227 |
| Grifols USA, LLC | 10 | $185 |
| Johnson & Johnson | 5 | $167 |
| Regeneron Healthcare Solutions, Inc. | 6 | $162 |
| Mylan Specialty L.p. | 9 | $149 |
| Genentech USA, Inc. | 8 | $133 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $92 |
| Mayne Pharma Commercial LLC | 4 | $83 |
| Astellas Pharma US Inc | 5 | $77 |
| Philips North America LLC | 4 | $61 |
| Inogen, Inc. | 2 | $47 |
| Merck | 3 | $43 |
| Portola Pharmaceuticals, LLC | 3 | $43 |
| Baxter Healthcare | 2 | $42 |
| Amgen | 2 | $36 |
| Electromed, Inc. | 3 | $35 |
| Advanced Respiratory, Inc | 2 | $35 |
| Medical Device Business Services, Inc. | 2 | $34 |
| Shockwave Medical, Inc | 1 | $26 |
| Covis Pharma GmbH | 1 | $25 |
| Medtronic | 1 | $23 |
| Actelion Pharmaceuticals US, Inc. | 1 | $21 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Veran Medical Technologies, Inc. | 1 | $18 |
| Insmed, Inc. | 1 | $18 |
| Haemonetics Corporation | 1 | $15 |
| Resmed Corp | 1 | $14 |
| United Therapeutics Corporation | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$169
- TEZSPIRE$169
- AIRSUPRA$169
- CHARTIS CATHETER$150
- ZEPHYR DELIVERY CATHETER$150
- ZEPHYR ENDOBRONCHIAL VALVE$150
- PULMONX CHARTIS TABLET CONSOLE$150
- NUCALA$122
How this compares
$4,071 in reported general payments places this provider in the 85th percentile of 285 critical care medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 340 | $311,734 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 149 | $117,937 |
| Dupixent PenDupilumab | 24 | $88,574 |
| Breo ElliptaFluticasone/Vilanterol | 185 | $87,284 |
| Spiriva RespimatTiotropium Bromide | 33 | $23,609 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 37 | $23,084 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 16 | $20,719 |
| SymbicortBudesonide/Formoterol Fumarate | 55 | $16,011 |
| DuleraMometasone/Formoterol | 20 | $7,898 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 262 | $7,725 |
| Advair HfaFluticasone Propion/Salmeterol | 20 | $6,260 |
| Incruse ElliptaUmeclidinium Bromide | 15 | $5,493 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 49 | $5,133 |
| Wixela InhubFluticasone Propion/Salmeterol | 29 | $3,020 |
| Ventolin HfaAlbuterol Sulfate | 36 | $2,448 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $1,003 | $427,595577 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $506 | $133,948204 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $299 | $44,32749 claims |
| MerckDulera | $43 | $7,89820 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 285 critical care medicine providers in Ohio.
Other critical care medicine in Cincinnati
- Sadia BenzaquenCincinnati$15K
- Maria IndiharCincinnati$8K
- Geoffrey LohCincinnati$7K
- Kiranmayee LankaCincinnati$6K
- Thomas PrestonCincinnati$5K
- Muhammad KhawarCincinnati$5K
- Christopher OrabellaCincinnati$5K
- Adam ColeCincinnati$4K
- Christopher SchmittCincinnati$4K
- Jonathan HendersonCincinnati$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.